MAPK7 and cancer: Notably, ERK5 inhibitors have been used to sensitize cancer cells in various combination therapies, including TRAIL-based treatments, further supporting the rationale for developing ERK5 inhibitors for clinical use (Carmell et al, 2021; Espinosa-Gil et al, 2023).